A Randomized, Placebo-Controlled, Double-Blind, Dose-Response, Phase 2, -Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Dose-Response, Phase 2, -Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Risperidone (Primary)
  • Indications Hot flashes; Vasomotor symptoms
  • Focus Therapeutic Use
  • Acronyms RDC
  • Sponsors Yung Shin Pharmaceutical
  • Most Recent Events

    • 14 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
    • 08 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top